Intellia has reported positive results from a phase 3 trial of its therapy for hereditary angioedema, with some reports indicating a significant reduction in attacks. The therapy, which involves in vivo gene editing, may have shown efficacy in a high percentage of patients, with one report suggesting 62% of patients were attack- and therapy-free after a single dose. The exact outcomes and details of the trial results are not entirely clear, but the news appears to be positive for Intellia's treatment.